Lapatinib and breast cancer: current indications and outlook for the future

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience

(2010) S Sutherland et al.   BRITISH JOURNAL OF CANCER

Pilot Neoadjuvant Trial with Combination of Lapatinib and Nab-Paclitaxel in HER2+ Breast Cancer.:

(2010) V. Kaklamani et al.   CANCER RESEARCH

PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).

(2010) I Migliaccio et al.   CANCER RESEARCH

Mechanisms of resistance to HER family targeting antibodies

(2010) Tim J. Kruser et al.   EXPERIMENTAL CELL RESEARCH

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

(2009) G. Capri et al.   ANNALS OF ONCOLOGY

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety and biomarker results from Japanese patients phase II studies

(2009) M Toi et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

(2009) H. A. Burris et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib

(2009) Gianluca Tomasello et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to W.F. Pirl et al

(2009) Jeffrey A. Morgan et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

(2008) H. J. Burstein et al.   ANNALS OF ONCOLOGY

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial)

(2008) Valentina Guarneri et al.   Clinical Breast Cancer

Jumping higher: is it still possible? The ALTTO trial challenge

(2008) Gianluca Tomasello et al.   Expert Review of Anticancer Therapy

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain

(2008) B. Gril et al.   JNCI-Journal of the National Cancer Institute

BRCA1p.Val1688del Is a Deleterious Mutation That Recurs in Breast and Ovarian Cancer Families From Northeast Italy

(2007) Sandro Malacrida et al.   JOURNAL OF CLINICAL ONCOLOGY